Alumni Network
Group Websites
Broking & Distribution
Asset Management
Private Wealth Management
Home Finance
Private Equity-Growth Capital
contact us
nifty
22,152.25
156.40 (0.71%)
19-Apr-2024 | 14:34
sensex
72,974.40
485.41 (0.67%)
19-Apr-2024 | 14:43
MOFSL
2,226.20
140.55 (6.74%)
19-Apr-2024 | 14:34
About MOFSL
History
Milestones
Core Purpose & Values
Technology
Customers
Partners / Business Associates
Employees
Apps
MO Foundation
ESG Profile
Our Businesses
Financial Services
Broking & Distribution
Asset Management
Private Wealth
Home Finance
Institutional Equities
Private Equity
Investment Banking
Overview
Offerings
Transactions
Prospectus
Offer Documents
Placement Documents
Delisting Documents
Track Record
Investor Grievances
Investor Charter
Research
Economy
Sector
Expert Opinion
Thematic
Investor Relations
ESG Profile
Fact Sheet
Financial Report
Quarterly
Standalone
Consolidated
Earning Presentation
Additional Slides
Concall Transcript
Concall Recording
Annual
Financial Statement of Subsidiaries
Share Holding Pattern
Additional Disclosures
Disclosures
Mandatory
Special
Unclaimed Dividends
IEPF
Buyback
Scheme of arrangement
NCD Public Issues
Corporate Policies & Codes
Careers
Overview
Career Path
Life at Motilal Oswal
Current Openings
Media Room
Press Release
Interviews
Print
Online
Television
News
Print
Online
Television
MOFSL in News
Advertisements
Print
Television
AV
Downloads
Corner Office
Back
Glaxosmithkline Consumer Healthcare Ltd.: New products expected to drive growth
+ Share
19-Feb-2018
Health food drinks (HFD) category is showing signs of a recovery, albeit on a low base. GlaxoSmith Kline Consumer Healthcare's (GSKC) market share, too, has been rebounding in recent months, the impact of which, however, is yet to be reflected in its financial results.
There are now new insights (e.g. better understanding of what consumer wants) emerging in the HFD category and also for GSKC.
While both the new products- Growth Plus and Protein Plus - are premium, there is willingness to trade-off profitability for overall growth. Unlike its earlier stance, price action is likely to be driven by commodity costs rather than setting a fixed number over inflation.
view report
Download report
open an account
trade now
If you are an Institutional Investor registered in EU, please know you are proceeding to a Research Portal on which Research Reports are available without any restriction. Accessing free Research Services is disallowed under the MIFID II Directive.
In case you are our registered EU client or are based outside EU, please click "I Confirm" to proceed
x